Drug Profile
Research programme: PROK2 - Seattle Life Sciences
Alternative Names: PROK2 antagonists; Prokineticin 2Latest Information Update: 10 Sep 2010
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Seattle Life Sciences
- Class Proteins
- Mechanism of Action PROK 2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 10 Sep 2010 Discontinued - Preclinical for Undefined indication in USA (Parenteral)
- 05 May 2009 Preclinical trials in Undefined indication in USA (Parenteral)